Autoimmune Disease Series: Strategies for Success in the Challenging Sjögren’s Syndrome MarketDecision ResourcesDecember 16, 2008 33 Pages - SKU: DECR2066394 |
|
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
4/30/2012 | published by: GBI Research
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments Summary GBI Research, the leading business intelligence provider, has released its latest
|
more...
|
$3,500.00
|
|
Systemic Lupus Erythematosus – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Systemic Lupus Erythematosus – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Systemic Lupus Erythematosus - Pipeline Review, H1 2012', provides an overview of the Systemic Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic
|
more...
|
$500.00
|
|
Psoriasis – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
Psoriasis – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Psoriasis - Pipeline Review, H1 2012', provides an overview of the Psoriasis therapeutic pipeline. This report provides information on the therapeutic development for Psoriasis, complete with latest
|
more...
|
$500.00
|
|
Auto Inflammatory Disease - Pipeline Review, H2 2011
11/28/2011 | published by: Global Markets Direct
Auto Inflammatory Disease - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Auto Inflammatory Disease - Pipeline Review, H2 2011', provides an overview of the Auto Inflammatory Disease therapeutic pipeline. This report provides
|
more...
|
$500.00
|
|
Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2011
11/28/2011 | published by: Global Markets Direct
Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Acquired (Autoimmune) Hemolytic Anemia - Pipeline Review, H2 2011', provides an overview of the Acquired (Autoimmune) Hemolytic Anemia therapeutic pipeline.
|
more...
|
$500.00
|
|
Celiac Disease - Pipeline Assessment and Market Forecasts to 2019
12/5/2011 | published by: GlobalData
Celiac Disease - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, “Celiac Disease - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source
|
more...
|
$3,500.00
|
|
Liver Disease Treatments: The Global Market
1/1/2012 | published by: BCC Research
In 2009, the global market for drugs used to treat liver disease was worth approximately $12.4 billion. Sales in 2010 decreased and the market did not see much progress, causing overall global sales to remain
|
more...
|
$4,850.00
|
|
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
12/1/2011 | published by: GBI Research
Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market Summary GBI Research, the leading business intelligence provider, has released its latest research “Monoclonal
|
more...
|
$3,500.00
|
|
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success
2/14/2012 | published by: GBI Research
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success Summary GBI Research, the leading business intelligence provider, has released its latest research, “Endpoints - Clinical Trials
|
more...
|
$3,500.00
|
|
Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases
6/1/2011 | published by: Decision Resources
Despite ongoing research in drug safety and efficacy, even physicians agree that the ability to predict response to high-priced autoimmune biologics is a largely untapped field. Biomarkers are the ideal vehicles to elucidate information about
|
more...
|
$4,600.00
|
Related Markets
Autoimmune Reports
- Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
- Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success
- Liver Disease Treatments: The Global Market
- Celiac Disease - Pipeline Assessment and Market Forecasts to 2019
- Orphan Autoimmune Disorders to 2017 - Strong Performance by Nplate and Promacta and Future Launches of Immunoglobulin Therapies will Drive the ITP Market
